Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine

Journal of Preventive Medicine and Hygiene

Volumn 53, Issue 2, 2012, Pages 68-77

  Durando, P ^a,b   Alicino, C ^a,b   De Florentiis, D ^a,b   Martini, M ^a,b   Icardi, G ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Children and adult vaccination; Effectiveness; Immunogenicity; Pneumococcal conjugate vaccine

Indexed keywords

13 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACUTE OTITIS MEDIA; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION CONTROL; LICENSING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TREATMENT INDICATION; VACCINATION;

CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; INFANT; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 84864714198     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: WB Saunders Company 1999, pp. 553-607.
2. World Health Organization (WHO). Pneumococcal conjugate vaccine for childhood immunization WHO position paper. Wkly Epidemiol Rec 2007;12:93-104.
3. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007;369:1179-86. (Pubitemid 46527876)
4. Centers for Disease Control and Prevention (CDC). Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997-2006. MMWR Morb Mortal Wkly Rep 2009;58:1-4.
5. Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007;161:1162-8. (Pubitemid 350223571)
6. Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with Pneumococcal Conjugate Vaccine on outpatient medical care visits in the United States. Pediatrics 2006;118:865-873. (Pubitemid 46090026)
7. Zhou F, Shefer A, Kong Y, et al. Trends in acute otitis mediarelated health care utilization by privately insured young children in United States, 1997-2004. Pediatrics 2008;121:253-60. (Pubitemid 351198446)
8. Durando P, Crovari P, Ansaldi F, et al. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009;27:3459-62.
9. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196:1346-54. (Pubitemid 351412007)
10. Richter SS, Richter SS, Heilmann KP, et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009;48:e23-33.
11. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009;360:244-56.
12. Pilishvili T, Lexau C, Farley M, et al. Sustained reductions in invasive pneumoccocal disease in the era of conjugate vaccine. J Infect Dis 2010;201:302-41.
13. Vintiñi E, Villena J, Alvarez S, et al. Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumococcal infection in young mice. Clin Exp Immunol 2008;52:399-409.
14. Wu K, Zhang X, Shi J, et al. Immunization with a combination of three pneumococcal proteins confers an additive and broad protection against Streptococcus pneumoniae infections in mice. Infect Immun 2010;78:1276-83.
15. Lu YJ, Forte S, Thompson CM, et al. Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun 2009;77:2076-83.
16. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54:893-97.
17. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008;57:144-8.
18. Whitney CG, Farley MM, Hadler J, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46. (Pubitemid 36514704)
19. Shafinoori S, Ginocchio CC, Greenberg AJ, et al. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr Infect Dis J 2005;24:10-6. (Pubitemid 40353310)
20. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004;23:485-9. (Pubitemid 38802290)
21. McBean A, Park YT, Caldwell D, et al. Declining invasive pneumococcal disease in the U.S. elderly. Vaccine 2005;23:5641-5. (Pubitemid 41613748)
22. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043-51. (Pubitemid 41539937)
23. Kellner JD, Church DL, MacDonald J, et al. Progress in the prevention of pneumococcal infection. CMAJ 2005;173:1149-51. (Pubitemid 41634913)
24. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus Pneumoniae. N Engl J Med 2006;354:1455-63.
25. Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of Macrolide resistance in Streptococcus Pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005;365:855-63. (Pubitemid 40332163)
26. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004;113:443-449. (Pubitemid 38280781)
27. Bettinger JA, Scheifele DW, Kellner JD, et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010;28:2130-6.
28. Kaye P, Andrews N, Slack M, et al. Vaccine effectiveness and indirect protection from pneumococcal conjugate vaccine used in a 2 dose infant priming plus booster schedule in England and Wales. 6th ISPPD 8-12 June 2008, Reykjavik, Iceland (Poster presentation).
29. Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008;26:3277-81.
30. Lepoutre A, Varon E, Georges S, et al. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveil 2008;13:18962.
31. Dubos F, Marechal I, Husson MO, et al. Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France. Arch Dis Child 2007;92:1009-12. (Pubitemid 350043977)
32. Harboe ZB, Valentiner-Branth P, Benfield TL, et al. Early effectiveness of heptavalent conjugate pneumoccal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Program. Vaccine 2010;28:2642-7.
33. th November 2001. Available at http://www.normativasanitaria.it/normsanpdf/0000/23681-1.pdf [Last accessed 29th March 2012].
34. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007;119:707-15. (Pubitemid 46556669)
35. Palmu AA, Herva E, Savolainen H, et al. Association of clinical signs and symptoms with bacterial findings in acute otitis media. Clin Infect Dis 2004;38:234-42. (Pubitemid 38113032)
36. Fletcher MA, Fritzell B. Brief review of the clinical effectiveness of Prevenar against otitis media. Vaccine 2007;25:2507-12. (Pubitemid 46394514)
37. Centers for Disease Control and Prevention (CDC). Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59.
38. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010;125:429-36.
39. Dortet L, Ploy MC, Poyart C, et al. Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis 2009;65:49-57.
40. Vestrheim DF, H?by EA, Bergsaker MR, et al. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 2010;28:2214-21.
41. Resti M, Moriondo M, Cortimiglia M, et al. Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real time polymerase chain reaction using blood samples. Clin Infect Dis 2010;51:1042-9.
42. Ansaldi F, de Florentis D, Canepa P, et al. Epidemiological changes after PCV7 implementation in Italy: perspective for new vaccines. Hum Vaccin 2011;7:211-6.
43. Ansaldi F, de Florentiis D, Canepa P, et al. Carriage of Streptoccoccus pneumoniae 7 years after implementation of vaccination program in a population with very high and long-lasting coverage, Italy. Vaccine 2012;30:2288-94.
44. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccinen Immunol 2010;17:1017-26.
45. Grimprel E, Laudat F, Patterson S, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine 2011;29:9675-83.
46. Italian Ministry of Health. Recommendations for administration of 13-valent pneumococcal vaccination in paediatric age. Circular of 27th May 2010.
47. Weycker D, Strutton D, Edelsberg J, et al. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010;28:4955-60.
48. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009;64:1062-9.
49. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012;67:71-9.
50. Alicino C, Iudici R, Alberti M, et al. The dangerous synergism between influenza and Streptococcus pneumoniae and innovative perspectives of vaccine prevention. J Prev Med Hyg 2011;52:102-6.
51. Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharideprotein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007;25:4029-37. (Pubitemid 46616998)
52. De Roux A, Schmöle-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008;46:1015-23. (Pubitemid 351589866)
53. st ECCMID, 7-10 May 2011, Milan, Italy (poster presentation).
54. st ECCMID, 7-10 May 2011, Milan, Italy (poster presentation)
55. Schwarz TF, Flamaing J, Rümke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥ 65 years. Vaccine 2011;29:5195-202.
56. The Committee for Medicinal Products for Human Use. European Medicines Agency. Prevenar 13. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed). Available at http://www.ema.europa.eu/docs/en-GB/document-library/ Summary-of-opinion/human/001104/WC500112838.pdf [Last accessed 29th March 2012].
57. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008;66:378-83.